ITEM 1. FINANCIAL STATEMENTS
See accompanying notes to these condensed consolidated financial statements.
See accompanying notes to these condensed consolidated financial statements.
See accompanying notes to these condensed consolidated financial statements.
See accompanying notes to these condensed consolidated financial statements.
See accompanying notes to these condensed consolidated financial statements.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1: Business Overview
GW Pharmaceuticals plc and its subsidiaries (referred to herein as “we,” “us,” “our,” and the “Company”) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our proprietary cannabinoid product platform in a broad range of disease areas. The Company is developing a portfolio of cannabinoid medicines, of which the lead product is
Epidiolex
®
, an oral medicine for the treatment of certain refractory childhood epilepsies.
The Company is a public limited company, which has had American Depository Shares (ADSs) registered with the U.S. Securities and Exchange Commission (SEC) and has been listed on Nasdaq since May 1, 2013. The Company’s ADSs each represent twelve ordinary shares of GW Pharmaceuticals plc
.
The Company is incorporated and domiciled in the United Kingdom. The address of the Company’s registered office and principal place of business is Sovereign House, Vision Park, Histon, Cambridgeshire.
Note 2: Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company’s Annual Report on Form 10-KT for the three-month transition period ended December 31, 2018. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods.
The condensed consolidated balance sheet as of December 31, 2018 was derived from audited annual financial statements but does not include all annual disclosures required by U.S. GAAP. These interim financial statements should be read in conjunction with the audited financial statements for the transition period ended December 31, 2018 included in our Annual Report on Form 10-KT. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year or any other future periods.
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Fair Value of Financial Instruments
The carrying values of the Company’s financial instruments, consisting of cash and cash equivalents, trade receivables, interest and other receivables, and accounts payable and accrued liabilities, approximate fair value due to the relative short-term nature of these instruments.
6
Accounts Receivable
Accounts receivable are recorded net of customer allowances for prompt payment discounts, chargebacks, and doubtful accounts. Allowances for prompt payment discounts and chargebacks are based on contractual terms. The Company estimates the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of its customers and individual customer circumstances. As of June 30, 2019 and December 31, 2018, the Company determined that an allowance for doubtful accounts was not required and no accounts were written off during the periods presented.
Inventory
Inventory is stated at the lower of cost or estimated net realizable value. The Company uses a combination of standard and actual costing methodologies to determine the cost basis for its inventories which approximates actual cost. Inventory is valued on a first-in, first-out basis. The Company reduces its inventory to net realizable value for potentially excess, dated or obsolete inventory based on an analysis of forecasted demand compared to quantities on hand, as well as product shelf life.
The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed. Prior to approval of Epidiolex by the United States Food and Drug Administration (FDA), all costs related to the manufacturing of Epidiolex were charged to research and development expense in the period incurred.
Revenue Recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Accounting Standards Codification (ASC) Topic 606,
Revenue from Contracts with Customers
(Topic 606), the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Revenue for the Company’s product sales has not been adjusted for the effects of a financing component as the Company expects, at contract inception, that the period between when the Company’s transfers control of the product and when the Company receives payment will be one year or less. Product shipping and handling costs are included in cost of product sales.
Epidiolex Product Net Sales
Epidiolex was approved by the FDA in June 2018. Subsequent to the approval by the FDA, the United States Drug Enforcement Agency (DEA) took action to change the classification of Epidiolex from a Schedule I controlled substance to a Schedule V controlled substance, thereby allowing Epidiolex to be prescribed and distributed in the United States. On November 1, 2018, the Company launched sales of Epidiolex to specialty pharmacies (SPs) and specialty distributors (SDs). The Company recognizes revenue from product sales upon receipt of product at the SPs and SDs, the date at which the control is transferred, net of the following allowances which are reflected either as a reduction to the related account receivable or as an accrued liability, depending on how the allowance is settled:
Distribution Fees
: Distribution fees include distribution service fees paid to the SPs and SDs based on a contractually fixed percentage of the wholesale acquisition cost (WAC), and prompt payment discounts. Distribution fees are recorded as an offset to revenue based on contractual terms at the time revenue from the sale is recognized.
7
Rebates
: Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program and the Medicare Part D prescription drug benefit
, and contractual rebates with commercial payers
. Rebates are amounts owed after the final dispensing of the product to a benefit plan participant and are based upon contractual agreements with, or statutory requirements pertaining to, Medicaid and Medicare benefit providers. The allowance for rebates is based on statutory discount rates and expected utilization. The Company’s estimates for expected utilization of rebates is based on utilization data received from the SPs since product launch. Rebates are generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter’s activity, plus an accrual balance for prior quarters’ unpaid rebates. If actual future rebates vary from estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.
Chargebacks
: Chargebacks are discounts and fees that relate to contracts with government and other entities purchasing from the SDs at a discounted price. The SDs charge back to the Company the difference between the price initially paid by the SDs and the discounted price paid to the SDs by these entities. The Company also incurs group purchasing organization fees for transactions through certain purchasing organizations. The Company estimates sales with these entities and accrues for anticipated chargebacks and organization fees, based on the applicable contractual terms. If actual future chargebacks vary from these estimates, the Company may need to adjust prior period accruals, which would affect revenue in the period of adjustment.
Co-Payment Assistance
: The Company offers co-payment assistance to commercially insured patients meeting certain eligibility requirements. Co-payment assistance is accrued for based on actual program participation and estimates of program redemption using data provided by third-party administrators.
Product Returns
: Consistent with industry practice, the Company offers the SPs and SDs limited product return rights for damages, shipment errors, and expiring product, provided that the return is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company does not allow product returns for product that has been dispensed to a patient. As the Company receives inventory reports from the SPs and SDs and has the ability to control the amount of product that is sold to the SPs and SDs, it is able to make a reasonable estimate of future potential product returns based on this on-hand channel inventory data and sell-through data obtained from the SPs and SDs. In arriving at its estimate, the Company also considers historical product returns, the underlying product demand, and industry data specific to the specialty pharmaceutical distribution industry.
The total amount deducted from gross sales for the allowances described above for the three and six months ended June 30, 2019 was $14.5 million and $22.0 million, respectively
.
Sativex Product Net Sales
Sales of Sativex, which is currently being commercialized for spasticity due to multiple sclerosis (MS) outside the United States, are
made pursuant to license agreements with commercial partners
. The Company has entered into license agreements for the commercialization of Sativex in Europe, Canada, Israel, Mexico, and South America. Under these license agreements, the Company sells fully labeled Sativex vials to its commercial partners for a contractually agreed price, which is generally based on percentages of the commercial partners’ in-market net selling price charged to end customers. Product net sales revenue related to Sativex shipments to commercial license partners is recognized when shipped, the date at which the control is transferred. The Company commercializes Sativex in Australia and New Zealand through a consignment relationship with a local distributor. Product net sales revenue related to Sativex sales in Australia and New Zealand are recognized when the product is sold through to the end customer.
Other Revenue
The Company’s other revenue primarily consists of research and development fee revenue for research and development services provided under a collaboration agreement with
Otsuka Pharmaceutical Co. Ltd (Otsuka)
that was terminated in December 2017 and variable consideration milestone payments related to the Sativex license agreements.
The research and development fee revenue is recognized at the time the underlying services are performed.
8
The Sativex license agreements contain provisions for the Company to earn variable consideration in the form of regulatory milestone payments, sales-based milestone payments, and royalty payments. The Company has no further performance obligations related to the regulatory milestone payments and these amounts are recognized in accordance with Topic 606 when receipt of these payments becomes probable and there is no significant risk of revenue reversal. Revenue related to the sales-based milestone payments and product royalty payments are subject to the sales-based royalty exception under Topic 606 and will be recognized when the underlying sales are made.
Research and Development Expenses
Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As actual costs become known, the Company adjusts its accruals accordingly.
Research
and development expense is presented net of reimbursements from reimbursable tax and expenditure credits from the U.K. government. Reimbursable
research and development tax and expenditure credits were $0.7 million and $1.5 million for the three and six months ended June 30, 2019 respectively, compared to $0.5 million and $1.6 million for the same periods in 2018.
Concentration Risk
Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and accounts receivable. The Company’s cash and cash equivalents balances are primarily in depository accounts at major financial institutions in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.
Share-based Compensation
The Company recognizes share-based compensation expense for grants of stock options under the Company’s Long-Term Incentive Plans to employees and non-employee members of the Company’s board of directors based on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over the award’s requisite service period. Expense related to awards with graded vesting is generally recognized over the vesting period using the accelerated attribution method.
Income Taxes
The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
For UK tax purposes, the $104.1 million gain on the sale of the priority review voucher (PRV) is expected to be fully offset by current year operating tax losses generated in the UK.
9
Uncertain tax positions, for which management's assessment is that there is more than a 50% probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to certain recognition and measurement criteria. The Company re-evaluates uncertain tax positions and considers various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position. The Company adjusts the level of the liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. The Company recognizes interest and penalties related to income tax matters in income tax expense
.
New Accounting Pronouncements
On January 1, 2019, the Company adopted a new accounting standard issued by the Financial Accounting Standards Board (FASB) on accounting for leases using the modified retrospective method. This new accounting standard requires a lessee to recognize an asset and liability for most leases on its balance sheet. The Company elected the optional transition method that allowed for a cumulative-effect adjustment as of January 1, 2019 and did not restate previously reported results in the comparative periods. The Company also elected to adopt certain practical expedients allowed by the new standard, which among other things, allowed the Company to carry forward its historical lease classification.
As a result of adoption of the new standard, the Company recorded operating lease assets and liabilities of approximately $20.5 million and $21.1 million, respectively as of January 1, 2019. The operating lease liability was determined based on the present value of the remaining minimum rental payments and the operating lease asset was determined based on the value of the lease liability, adjusted for existing deferred rent balances, which were previously included in other current liabilities and other liabilities. Accounting for the Company’s finance leases remains substantially unchanged. As a result of the adoption of the new leasing accounting standard, the Company’s build-to-suit asset has been reclassified to buildings and the build-to-suit financing obligation has been reclassified to finance lease obligation in the condensed consolidated balance sheets. The adoption of the new standard did not materially impact the Company’s consolidated results of operations or cash flows.
In addition, the adoption of this new accounting standard resulted in increased qualitative and quantitative disclosures regarding the amount, timing, and uncertainty of cash flows arising from leases. For further details, see Note 9
Leases
.
Note 3: Fair Value Measurements
At June 30, 2019 and December 31, 2018, the Company’s cash equivalents consisted of money market funds, which are classified as Level 1 within the fair value hierarchy defined by authoritative guidance.
Investment securities classified as Level 1 are valued using quoted market prices.
The Company does not hold any securities classified as Level 2, which are securities valued using inputs that are either directly or indirectly observable, or Level 3, which are securities valued using unobservable inputs. The Company has not transferred any investment securities between the classification levels.
Note 4: Composition of Certain Balance Sheet Captions:
Inventory consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
Raw materials
|
|
$
|
1,375
|
|
|
$
|
676
|
|
Work in process
|
|
|
52,567
|
|
|
|
28,709
|
|
Finished goods
|
|
|
6,100
|
|
|
|
3,645
|
|
|
|
$
|
60,042
|
|
|
$
|
33,030
|
|
10
Property, plant and equipment, net, consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
Buildings
|
|
$
|
4,567
|
|
|
$
|
4,573
|
|
Machinery and equipment
|
|
|
34,402
|
|
|
|
32,598
|
|
Leasehold improvements
|
|
|
36,560
|
|
|
|
36,004
|
|
Office and IT equipment
|
|
|
2,769
|
|
|
|
2,481
|
|
Construction-in-process
|
|
|
62,067
|
|
|
|
44,546
|
|
|
|
|
140,365
|
|
|
|
120,202
|
|
Accumulated depreciation
|
|
|
(33,033
|
)
|
|
|
(29,370
|
)
|
|
|
$
|
107,332
|
|
|
$
|
90,832
|
|
Depreciation of property and equipment was $2.1 million and $2.2 million for the three months ended June 30, 2019 and 2018, respectively. Depreciation of property and equipment was $4.2 million and $4.4 million for the six months ended June 30, 2019 and 2018, respectively. The Company did not have any significant property, plant, or equipment write-offs in the three or six months ended June 30, 2019 and 2018.
Accrued liabilities consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
Accrued compensation and benefits
|
|
$
|
15,992
|
|
|
$
|
18,482
|
|
Accrued vendor fees
|
|
|
17,591
|
|
|
|
11,452
|
|
Clinical trial accruals
|
|
|
10,051
|
|
|
|
10,059
|
|
Accrued growing fees
|
|
|
3,038
|
|
|
|
2,717
|
|
Accrued sales rebates and discounts
|
|
|
11,091
|
|
|
|
628
|
|
Other
|
|
|
8,671
|
|
|
|
9,139
|
|
|
|
$
|
66,434
|
|
|
$
|
52,477
|
|
Other current liabilities consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
Finance lease liabilities
|
|
$
|
287
|
|
|
$
|
400
|
|
Operating lease liabilities
|
|
|
4,594
|
|
|
|
—
|
|
Landlord financing
|
|
|
556
|
|
|
|
539
|
|
Other
|
|
|
320
|
|
|
|
620
|
|
|
|
$
|
5,757
|
|
|
$
|
1,559
|
|
Other liabilities consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
Landlord financing obligation
|
|
$
|
9,136
|
|
|
$
|
9,434
|
|
Other
|
|
|
126
|
|
|
|
648
|
|
|
|
$
|
9,262
|
|
|
$
|
10,082
|
|
11
Note 5: Earnings per share
The computation of basic earnings per share (EPS) is based on the weighted-average number of our ordinary shares outstanding. For the purpose of this calculation, vested nominal strike-price options are considered ordinary shares outstanding. The computation of diluted EPS is based on the weighted-average number of ordinary shares outstanding and potentially dilutive common stock equivalents outstanding for the period, primarily shares that may be issued under the Company’s stock option plans, determined using the treasury stock method.
The Company incurred net losses for the three and six months ended June 30, 2018 and therefore did not include potentially dilutive common stock equivalents in the computation of diluted net loss per share. For the three and six months ended June 30, 2018, options totaling approximately 12.7 million ordinary shares were excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive.
The computation for basic and diluted EPS were as follows (in thousands, except per share amounts):
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands, except per share amounts)
|
|
Net income (loss) for basic and diluted EPS
|
|
$
|
79,748
|
|
|
$
|
(84,011
|
)
|
|
$
|
29,684
|
|
|
$
|
(153,472
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares for basic EPS
|
|
|
371,712
|
|
|
|
340,457
|
|
|
|
370,776
|
|
|
|
340,355
|
|
Effect of dilutive securities
|
|
|
5,723
|
|
|
|
—
|
|
|
|
5,898
|
|
|
|
—
|
|
Weighted-average shares for diluted EPS
|
|
|
377,435
|
|
|
|
340,457
|
|
|
|
376,674
|
|
|
|
340,355
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic EPS
|
|
$
|
0.21
|
|
|
$
|
(0.25
|
)
|
|
$
|
0.08
|
|
|
$
|
(0.45
|
)
|
Diluted EPS
|
|
$
|
0.21
|
|
|
$
|
(0.25
|
)
|
|
$
|
0.08
|
|
|
$
|
(0.45
|
)
|
Note 6: Stockholders’ Equity
In October 2018, the Company completed a public offering of 2,185,000 ADSs listed on the Nasdaq Global Market, representing 26,220,000 ordinary shares of the Company, at a price of $158.00 per ADS. The net proceeds from this transaction after underwriting discounts and commissions were approximately $324.6 million.
Note 7: Share-Based Compensation
Compensation expense for share-based awards is recognized over the requisite service period using the accelerated attribution method.
An estimated forfeiture rate has been applied to unvested awards for the purpose of calculating
compensation cost. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
The fair value of stock option awards is estimated using the Black-Scholes option-pricing model. The determination of fair value using the Black-Scholes model is affected by the Company’s ADS price as well as assumptions regarding a number of complex and subjective variables, including expected ADS price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.
The Company estimates its stock price volatility using a combination of historical stock price volatility and the average implied volatility of options traded in the open market. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. The expected option life assumption is estimated using the simplified method prescribed by ASC Topic 718,
Compensation – Stock Compensation,
and is based on the mid-point between vest date and expiration date since the Company does not have sufficient exercise history to estimate expected option life of historical grants.
12
The table below summarizes the total share-based compensation expense included in the Company’s statements of operations for the periods presented:
|
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
Research and development
|
|
$
|
2,443
|
|
|
$
|
2,131
|
|
|
$
|
4,841
|
|
|
$
|
3,418
|
|
Sales, general and administrative
|
|
|
9,074
|
|
|
|
6,890
|
|
|
|
17,187
|
|
|
|
12,048
|
|
|
|
$
|
11,517
|
|
|
$
|
9,021
|
|
|
$
|
22,028
|
|
|
$
|
15,466
|
|
For the three months ended June 30, 2019 and 2018, $0.7 million and $0.5 million of share-based compensation related to manufacturing operations was capitalized into inventory, respectively. For the six months ended June 30, 2019 and 2018, $1.3 million and $1.0 million of share-based compensation related to manufacturing operations was capitalized into inventory, respectively.
Note 8: Commitments and Contingencies
As of June 30, 2019, the Company was not a party to any material legal proceedings.
The Company is not aware of any other proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations.
Note 9: Leases
The Company leases buildings, land, equipment, and automobiles. Additionally, the Company has growing and cultivation contracts that contain embedded facility leases. The Company determines if an arrangement is a lease or contains a lease at contract inception. For contracts that are or contain leases, the Company records right-of-use (ROU) lease assets and lease liabilities at lease commencement based on the present value of lease payments over the lease term. The lease term includes renewal option periods when those options are reasonably certain to be exercised. The present value of lease payments is calculated using the Company’s incremental collateralized borrowing rate unless an implicit rate is readily determinable. ROU lease assets include any upfront payments and exclude lease incentives.
The Company accounts for lease and non-lease components as a single lease component for all of its leases except embedded leases, for which the lease and non-lease components are accounted for separately.
Leases are classified at lease commencement as either operating leases or finance leases. Operating lease assets are included in non-current assets and operating lease liabilities are included in other current liabilities and operating lease liabilities in our condensed consolidated balance sheets. Operating lease cost is recognized on a straight-line basis over the lease term. Finance lease assets are included in property, plant and equipment, net, and finance lease liabilities are included in other current liabilities and finance lease liabilities in our condensed consolidated balance sheets. Finance lease cost is recognized as depreciation expense of fixed assets and interest expense on finance lease liabilities. Leases with an initial term of 12 months or less are not recorded in the consolidated balance sheets and expense for these leases is recognized on a straight-line basis over the lease term.
As of June 30, 2019, the Company has a lease agreement for office space that has not yet commenced with fixed lease payments totaling $3.2 million. The lease is expected to commence in the third quarter of 2019.
No operating or finance lease assets were exchanged for lease liabilities in the three or six months ended June 30, 2019.
13
The Company’s lease costs consist of the following:
|
|
Three Months Ended
June 30,
|
|
|
Six Months Ended
June 30,
|
|
|
|
2019
|
|
|
2019
|
|
|
|
(in thousands)
|
|
|
(in thousands)
|
|
Lease cost
|
|
|
|
|
|
|
|
|
Operating lease cost
(1)
|
|
$
|
1,827
|
|
|
$
|
3,250
|
|
Finance lease cost
|
|
|
|
|
|
|
|
|
Amortization of leased assets
|
|
|
96
|
|
|
|
194
|
|
Interest on lease liabilities
|
|
|
108
|
|
|
|
192
|
|
Total lease cost
|
|
$
|
2,031
|
|
|
$
|
3,636
|
|
|
(1)
|
Includes short-term lease expense and variable cost, which are immaterial.
|
For the three and six months ended June 30, 2019, approximately $0.8 million and $1.2 million of operating and finance lease cost related to manufacturing operations was capitalized into inventory, respectively.
The following table summarizes cash flow information related to the Company’s lease obligations:
|
|
Six Months Ended
June 30,
|
|
|
|
2019
|
|
|
|
(in thousands)
|
|
Operating cash used for operating leases
|
|
$
|
2,877
|
|
Operating cash used for finance leases
|
|
$
|
192
|
|
Financing cash used for finance leases
|
|
$
|
250
|
|
The following table summarizes the Company’s lease assets and liabilities:
|
|
As of June 30,
|
|
|
|
2019
|
|
|
|
(in thousands)
|
|
Lease assets
|
|
|
|
|
Operating lease assets
|
|
$
|
18,739
|
|
Finance lease assets
|
|
|
5,117
|
|
Total lease assets
|
|
$
|
23,856
|
|
|
|
|
|
|
Lease liabilities
|
|
|
|
|
Current
|
|
|
|
|
Operating lease liabilities
|
|
|
4,594
|
|
Finance lease liabilities
|
|
|
287
|
|
Non-current
|
|
|
|
|
Operating lease liabilities
|
|
|
15,139
|
|
Finance lease liabilities
|
|
|
5,536
|
|
Total lease liabilities
|
|
$
|
25,556
|
|
14
The following table summarizes other supplemental information related to the Company’s lease obligations:
|
|
As of June 30,
|
|
|
|
2019
|
|
Weighted average remaining lease term (years)
|
|
|
|
|
Operating leases
|
|
|
7.5
|
|
Finance leases
|
|
|
14.7
|
|
|
|
|
|
|
Weighted average discount rate
|
|
|
|
|
Operating leases
|
|
|
5.8
|
%
|
Finance leases
|
|
|
7.6
|
%
|
The Company’s future minimum annual lease payments under operating and finance leases as of June 30, 2019 are as follows:
|
|
Operating Leases
|
|
|
Finance Leases
|
|
|
|
(in thousands)
|
|
2019 (remaining 6 months)
|
|
$
|
2,346
|
|
|
$
|
371
|
|
2020
|
|
|
4,583
|
|
|
|
704
|
|
2021
|
|
|
3,703
|
|
|
|
704
|
|
2022
|
|
|
2,677
|
|
|
|
697
|
|
2023
|
|
|
1,953
|
|
|
|
694
|
|
2024
|
|
|
1,784
|
|
|
|
694
|
|
Thereafter
|
|
|
7,777
|
|
|
|
5,966
|
|
Total lease payments
|
|
$
|
24,823
|
|
|
$
|
9,830
|
|
Less amounts representing interest
|
|
|
5,090
|
|
|
|
4,007
|
|
Total lease obligations
|
|
$
|
19,733
|
|
|
$
|
5,823
|
|
Prior to January 1, 2019, the Company accounted for leases under the previous U.S. GAAP lease guidance, Accounting Standards Codification Topic 840,
Leases
. Rent expense for operating leases for the three months and six months ended June 30, 2018 was $1.1 and $2.1 million, respectively. The aggregate future minimum rent payments under leases in effect as of December 31, 2018 were $6.4 million in 2019, $6.9 million in 2020, $5.7 million in 2021, $4.2 million in 2022, $2.8 million in 2023, and $11.8 million thereafter.
Note 10: Sale of Priority Review Voucher
In April 2019, the Company sold the rare pediatric disease priority review voucher (PRV) it received from the FDA in connection with the United States approval of Epidiolex to Biohaven Pharmaceutical Holding Ltd. for consideration of $105.0 million. The net proceeds of $104.1 million from the sale of the PRV was recognized as a gain on the sale of an intangible asset within other income on the consolidated statements of operations, as the PRV did not have a carrying value on the Company’s consolidated balance sheet at the time of sale.
15